John K. Bakewell - May 21, 2024 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Director
Signature
/s/ Lisa Taylor as Attorney-in-fact for John K. Bakewell
Stock symbol
TMCI
Transactions as of
May 21, 2024
Transactions value $
$0
Form type
4
Date filed
5/22/2024, 05:30 PM
Previous filing
May 13, 2024
Next filing
Aug 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Award $0 +15.1K +11.17% $0.00 150K May 21, 2024 Direct F1, F2
holding TMCI Common Stock 250K May 21, 2024 by spouse as trustee of a trust
holding TMCI Common Stock 92.3K May 21, 2024 as trustee of a trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMCI Stock Option (Right to Buy) Award $0 +33.3K $0.00 33.3K May 21, 2024 Common Stock 33.3K $4.97 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 21, 2025 or (b) the date of the 2025 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the issuer's Common Stock issuable upon settlement of the RSUs until the earlier of (a) a change in control, (b) the Reporting Person's separation of service to the Issuer, or (c) the fifth anniversary of the RSU's grant date.
F2 Includes 15,091 restricted stock units.
F3 The stock option will vest in 12 substantially equal monthly installments, commencing on June 21, 2024, such that the stock option will be fully vested and exercisable on the earlier of (a) May 21, 2025, or (b) the date of the 2025 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through each vesting date.